Clinical Trial Update: A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating overall health, physical activity, and joint outcomes in people with severe or moderate Hemophilia A on emicizumab prophylaxis…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Severe Hemophilia A, Moderate Hemophilia A | Phase 4 | Status: ACTIVE_NOT_RECRUITING